Have you validated your product shipping?

According to the Code of Federal Regulations (21 CFR 211.150 Distribution procedures), each manufacturer must develop, maintain, and implement a written distribution procedure. 

(a)        A procedure whereby the oldest approved stock of a drug product is distributed first. Deviation from this requirement is permitted if such deviation is temporary and appropriate.

(b)        A system by which the distribution of each lot of drug product can be readily determined to facilitate its recall if necessary.

written distribution procedure for GMP pharmaceuticals

A company recently received the following 483 observation:

…. Written distribution procedures are not established.

Specifically, shipment of finished drug products using your firm’s components and containers have not been validated to ensure that temperature sensitive pharmaceuticals are consistently maintained within the designated temperature range during transit from your firm to the point of use, and that their identity, strength, quality, and purity are not affected.

For example, the firm repackaged and/or relabeled drug products that have refrigerated storage conditions, but you stated that you have not validated controlled-temperature shipping which include APIs and/or raw materials.

For more information on conducting stability studies, refer to FDA guidance document, Q1A(R2) Stability Testing of New Drug Substances and Products.

For more information on storage and transportation strategies, refer to USP General Chapter <1079> Risks and Mitigation Strategies for the Storage and Transportation of Finished Drug Products.

To view more observations pertaining to storage distribution and stability, refer to the following GMP Trends® Issues:  1075, 1072, 1070, 1065, 1045 and 1042.

Stay in Compliance! Subscribe today!

Become A Subscriber And Stay Ahead of the FDA

To get the most out of GMP Trends®, sign up to one of our subscription packages for valuable, up-to-date information you won't find anywhere else! Every subscription provides the most frequently cited FDA 483 observations taken from recent FDA Inspections. The non-essential information is redacted to streamline the facts in an easily readable format. Join the thousands of professionals who rely on GMP Trends® to keep them informed of the latest FDA Enforcement Trends!

SUBSCRIBE NOW